These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 22672360)

  • 1. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
    Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
    BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of SUMO-specific protease 1 (SENP1) in prostate cancer patients undergoing radical prostatectomy.
    Li T; Huang S; Dong M; Gui Y; Wu D
    Urol Oncol; 2013 Nov; 31(8):1539-45. PubMed ID: 23089540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-dopa decarboxylase (DDC) gene expression is related to outcome in patients with prostate cancer.
    Koutalellis G; Stravodimos K; Avgeris M; Mavridis K; Scorilas A; Lazaris A; Constantinides C
    BJU Int; 2012 Sep; 110(6 Pt B):E267-73. PubMed ID: 22571720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
    Giesing M; Suchy B; Driesel G; Molitor D
    BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.
    Fritzsche FR; Jung M; Tölle A; Wild P; Hartmann A; Wassermann K; Rabien A; Lein M; Dietel M; Pilarsky C; Calvano D; Grützmann R; Jung K; Kristiansen G
    Eur Urol; 2008 Nov; 54(5):1097-106. PubMed ID: 18061337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53INP1 overexpression in prostate cancer correlates with poor prognostic factors and is predictive of biological cancer relapse.
    Giusiano S; Garcia S; Andrieu C; Dusetti NJ; Bastide C; Gleave M; Taranger-Charpin C; Iovanna JL; Rocchi P
    Prostate; 2012 Feb; 72(2):117-28. PubMed ID: 21538421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
    Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
    Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.
    Savdie R; Horvath LG; Benito RP; Rasiah KK; Haynes AM; Chatfield M; Stricker PD; Turner JJ; Delprado W; Henshall SM; Sutherland RL; Kench JG
    BJU Int; 2012 Jun; 109(12):1794-800. PubMed ID: 21992536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer.
    Prtilo A; Leach FS; Markwalder R; Kappeler A; Burkhard FC; Cecchini MG; Studer UE; Thalmann GN
    J Urol; 2005 Nov; 174(5):1814-8; discussion 1818. PubMed ID: 16217293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
    Lee CT; Capodieci P; Osman I; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
    Clin Cancer Res; 1999 May; 5(5):977-83. PubMed ID: 10353729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a tertiary Gleason pattern 4 or 5 on clinical failure and mortality after radical prostatectomy for clinically localised prostate cancer.
    Servoll E; Saeter T; Vlatkovic L; Lund T; Nesland J; Waaler G; Axcrona K; Beisland HO
    BJU Int; 2012 May; 109(10):1489-94. PubMed ID: 21933333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cysteine-rich secretory protein 3 and β-microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome.
    Hoogland AM; Dahlman A; Vissers KJ; Wolters T; Schröder FH; Roobol MJ; Bjartell AS; van Leenders GJ
    BJU Int; 2011 Oct; 108(8):1356-62. PubMed ID: 21410630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.
    Huang SP; Huang CY; Wang JS; Liu CC; Pu YS; Yu HJ; Yu CC; Wu TT; Huang CH; Wu WJ; Chou YH; Wu MT
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6632-8. PubMed ID: 18006764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
    Miyake H; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
    Urol Oncol; 2010; 28(2):145-51. PubMed ID: 18848789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
    Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
    J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy.
    Voutsadakis IA; Vlachostergios PJ; Daliani DD; Karasavvidou F; Kakkas G; Moutzouris G; Melekos MD; Papandreou CN
    Urol Int; 2012; 88(2):158-64. PubMed ID: 22286396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients.
    Satoh T; Yang G; Egawa S; Addai J; Frolov A; Kuwao S; Timme TL; Baba S; Thompson TC
    Cancer; 2003 Mar; 97(5):1225-33. PubMed ID: 12599229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic predisposition to early recurrence in clinically localized prostate cancer.
    Borque Á; del Amo J; Esteban LM; Ars E; Hernández C; Planas J; Arruza A; Llarena R; Palou J; Herranz F; Raventós CX; Tejedor D; Artieda M; Simon L; Martínez A; Carceller E; Suárez M; Allué M; Sanz G; Morote J
    BJU Int; 2013 Apr; 111(4):549-58. PubMed ID: 22759231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.